Sparsentan
- Generic Name
- Sparsentan
- Brand Names
- Filspari
- Drug Type
- Small Molecule
- Chemical Formula
- C32H40N4O5S
- CAS Number
- 254740-64-2
- Unique Ingredient Identifier
- 9242RO5URM
- Background
Sparsentan is a dual antagonist of the endothelin type A receptor (ETR) and the angiotensin II (Ang II) type 1 receptor (ATR) with a similar affinity for both (9.3 nM for ETR and 0.8 nM for ATR). Sparsentan is first in its class and orally active, and was created by merging the structural elements of irbesartan, an ATR antagonist, and biphenylsulfonamide, an...
- Indication
Sparsentan is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.
- Associated Conditions
- Proteinuria
- Associated Therapies
- -
Jennifer Lai Yee, MD, PhD, MPH: Honing in on Sparsentan's Benefit in Genetic FSGS
Sparsentan showed a more pronounced antiproteinuric response in patients with genetic focal segmental glomerulosclerosis (gFSGS) compared to irbesartan, according to a posthoc analysis of the DUPLEX trial. Only 1 patient with gFSGS achieved complete remission with sparsentan, while 3 reached end-stage kidney disease with irbesartan. The study highlights the potential of sparsentan as a treatment option for this subgroup.
Travere Therapeutics Presents Data Reinforcing Clinical
Travere Therapeutics presented new data at ASN Kidney Week 2024 showing FILSPARI (sparsentan) effective in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS), with nearly 60% of IgAN patients achieving complete remission. Data also highlighted safety and efficacy in combination therapies and rapid, sustained proteinuria reduction in genetic FSGS patients.
Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes
Article references on obesity, diabetes, and kidney disease, including trends, treatments, and outcomes.
Otsuka eyes early filing of IgAN drug after phase 3 readout
Otsuka's anti-APRIL antibody sibeprenlimab showed significant reduction in uPCR in a phase 3 trial for IgA nephropathy, prompting potential FDA submission. Final results expected in 2026. Competitors include Novartis' zigakibart, Vertex's povetacicept, and Vera's atacicept.
Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI
Swissmedic grants temporary marketing authorization for FILSPARI, a treatment for primary IgA nephropathy, based on results from the Phase 3 PROTECT Trial. FILSPARI offers a once-daily, oral, non-immunosuppressive treatment, potentially replacing RASi in patients with IgAN.
Travere Therapeutics Secures Swiss Authorization For FILSPARI To Treat IgA Nephropathy
Swissmedic grants Travere Therapeutics and CSL Vifor temporary marketing authorization for FILSPARI in treating primary IgA nephropathy with high urine protein levels, following FDA and EMA approvals.
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI
Swissmedic grants temporary marketing authorization for FILSPARI, a treatment for primary IgA nephropathy, based on the PROTECT trial results. CSL Vifor and Travere Therapeutics anticipate providing access to this innovative therapy in Switzerland.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath